April 11, 2002
42 NPPA REVISES/FIXES PRICES OF 16 FORMULATION PACKS The National Pharmaceutical Pricing Authority has revised/fixed the prices of 16 formulation packs on April 10, 2002. Prices have been fixed for the first time in the case of 4 formulation packs. In the case of 12 packs, prices have been increased, ranging from 5.13% to 19.63%.Of the 16 formulation packs, ceiling prices (exclusive of excise duty and local taxes etc.) have been fixed in respect of 3 packs. Non-ceiling prices have been fixed in respect of the remaining 13 packs. Prices have been fixed/revised in accordance with the provisions of the DPCO, 1995 and as per the established criteria and guidelines. The statement showing the existing (where available) and revised prices is annexed. The information is also available on NPPAs website www.nppaindia.nic.in.
The formulations for which prices have been revised/fixed includes Pyrantel Pamoate which are used as anti-helminthics medicines, Insulin based formulations which are used in the treatment of diabities, Ephedrine combination which are used in the treatment of Ashtmaic disorders.
The prices fixed/revised would become effective within 15 days from the date of notification in the official gazette or the receipt of the order of the NPPA in this behalf, as per Para 14(1) of DPCO, 1995. The necessary revised price list is to be issued by the manufacturers/importers required under sub paragraph (3) of paragraph 14 of the DPCO, 1995. Accordingly, as per the provisions of the DPCO, the revised price list in Form-V is to be furnished by the concerned manufacturer(s) to the government/NPPA, State Drug Control Authorities and distributors, wholesalers and retailers, etc.
The manufacturers are also required to work out the pro-rata prices of different pack sizes as the case may be in terms of S.O. No. 83 (E) dated 27.01.98.
STATEMENT SHOWING THE PRICE FIXED/REVISED BY THE NATIONAL PHARMACEUTICAL PRICING AUTHORITY |
||||||
Agenda Item No. |
Company Name/ Formulation Name/Composition |
Pack Size |
Existing Price (Rs.) |
RP with ED (Rs.) |
%AGE Increase/ Decrease |
Remarks |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
(i) |
Non-Ceiling Packs | |||||
A |
IMPORTED CASES | |||||
I |
M/s. ELI LILY AND COMPANY (I) PVT. LTD. | |||||
1 |
Monocomponent Insulin | 3ml |
198.74 |
208.94 |
5.13 |
NCP |
Huminsulin NPH U100 cartridge | Cartridge |
|||||
(Human Insulin) | ||||||
Each ml contains | ||||||
Insulin Human-100 IU(as Isophane Insulin) | ||||||
Glycerol- 16mg | ||||||
Protamine Base - 0.27mg | ||||||
Di basic Sodium Phosphate, Zinc oxide | ||||||
with 1.6mg M-Cresol and 0.65mg | ||||||
Liquefied Phenol as preservative | ||||||
2 |
Monocomponent Insulin | 3ml |
198.74 |
208.94 |
5.13 |
NCP |
Huminsulin Regular U100 cartridge | Cartridge |
|||||
(Human Insulin) | ||||||
Each ml contains | ||||||
Insulin Human-100 IU(as neutral Insulin) | ||||||
Glycerol- 16mg and 2.5mg M-Cresol | ||||||
as preservative | ||||||
3 |
Monocomponent Insulin | 3ml |
198.74 |
208.94 |
5.13 |
NCP |
Huminsulin 30/70 U100 cartridge | Cartridge |
|||||
(Human Insulin) | ||||||
Each ml contains | ||||||
Insulin Human-100 IU (30% Neutral - | ||||||
Insulin & 70% as Isophane Insulin) | ||||||
Glycerol- 16mg and 0.189 Protamine base | ||||||
Zinc oxide with 1.6mg M-Cresol and | ||||||
0.65mg Liquefied Phenol as preservative | ||||||
II |
M/s. NOVO NORDISK (I) PVT. LTD. | |||||
4 |
Actrapid HM Vials | 10ml |
508.15 |
547.89 |
7.82 |
NCP |
Highly Purified Neutral Insulin | Vial |
|||||
(Monocomponent Human) | ||||||
Human Actrapid-100 IU/ml | ||||||
RP = Retail Price | ||||||
NCP = Non-ceiling Price specific to company/pack, inclusive of excise duty but exclusive of local taxes, etc. | ||||||
CP = Ceiling Price is exclusive of excise duty , local taxes, etc. | ||||||
Agenda Item No. |
Company Name/ Formulation Name/Composition |
Pack Size |
Existing Price (Rs.) |
RP with ED (Rs.) |
%AGE Increase/ Decrease |
Remarks |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
5 |
Monotard HM 100 IU Vials | 10ml |
508.15 |
544.66 |
7.18 |
NCP |
Highly Purified Insulin | Vial |
|||||
Zinc Suspension | ||||||
(Monocomponent Human) | ||||||
Human Monotard-100 IU/ml | ||||||
6 |
Mixtard 30 HM 100 IU Vials | 10ml |
508.15 |
543.63 |
6.98 |
NCP |
Mixture of Highly Purified | Vial |
|||||
Neutral Insulin | ||||||
Solution and Isophane Suspension | ||||||
(Monocomponent Human) | ||||||
Human Mixtard-100 IU/ml | ||||||
7 |
Actrapid HM Penfill 100 IU/ml | 5x3ml |
993.69 |
1044.70 |
5.13 |
NCP |
Highly Purified Neutral Insulin | Cartridge |
|||||
(Monocomponent Human) | ||||||
Actrapid HM Penfill-100 IU/ml | ||||||
8 |
Insulatard HM Penfill 100IU/ml | 5x3ml |
990.55 |
1044.70 |
5.47 |
NCP |
Highly Purified Isophane | Cartridge |
|||||
Insulin Suspension | ||||||
(Monocomponent Human) | ||||||
Insulatard HM Penfill-100IU/ml | ||||||
9 |
Mixtard 30 HM Penfill 100IU/ml | 5x3ml |
993.69 |
1044.70 |
5.13 |
NCP |
Mixture of Highly Purified | Cartridge |
|||||
Neutral Insulin | ||||||
Solution and Isophane Suspension | ||||||
(Monocomponent Human) | ||||||
Human Mixtard 30 HM Penfil-100IU/ml | ||||||
10 |
Mixtard 50 HM Penfill 100IU/ml | 5x3ml |
993.69 |
1044.70 |
5.13 |
NCP |
Mixture of Highly Purified | Cartridge |
|||||
Neutral Insulin | ||||||
Solution and Isophane Suspension | ||||||
(Monocomponent Human) | ||||||
Human Mixtard 50 HM Penfil-100IU/ml | ||||||
Agenda Item No. |
Company Name/ Formulation Name/Composition |
Pack Size |
Existing Price (Rs.) |
RP with ED (Rs.) |
%AGE Increase/ Decrease |
Remarks |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
B |
NEW CASES | |||||
III |
M.J. PHARMACEUTICALS LTD. | |||||
11 |
Huminsulin NPH | 10ml |
-- |
249.04 |
-- |
NCP |
Each ml contains | Vial |
|||||
Insulin Human 40 IU | ||||||
(Insulin Human of Recombinant DNA origin) | ||||||
Meta cresol (as preservative)- 0.16% w/v | ||||||
Phenol (as preservative) -0.065% w/v | ||||||
Water for Inj. - q.s. | ||||||
12 |
Huminsulin 30/70 | 10ml |
-- |
249.04 |
-- |
NCP |
Each ml contains | Vial |
|||||
Insulin Human - 40 IU | ||||||
(30% as Neutral Insulin & 70% as - | ||||||
Isophane Insulin suspension) | ||||||
(Insulin Human of Recombinant DNA origin) | ||||||
Meta cresol (as preservative)- 0.16% w/v | ||||||
Phenol (as preservative) -0.065% w/v | ||||||
Water for Inj. - q.s. | ||||||
IV |
M/s. NICHOLAS PIRAMAL (I) LTD. | |||||
13 |
Asmapax Depot Tablets (SR) | 10's |
-- |
6.14 |
-- |
NCP |
Each uncoated tab contains | Al_St |
|||||
Ephedrine resinate eq. to | ||||||
Ephedrine Hydrochloride-50mg | ||||||
Theophylline (anhydrous)-65mg | ||||||
(ii) |
Ceiling Packs | |||||
C |
REVISION CASES | |||||
14 |
Pyrantel Pamoate Tablets | 3's |
6.42 |
7.68 |
19.63 |
CP |
Each uncoated tab contains | Al_Bl |
|||||
Pyrantel Pamoate eq. to | ||||||
Pyrantel base-250mg | ||||||
15 |
Pyrantel Pamoate Suspension | 10ml |
-- |
8.82 |
-- |
CP |
Each 5ml contains | Bottle |
|||||
Pyrantel Pamoate eq. to | ||||||
Pyrantel base -250mg | ||||||
16 |
Pyrantel Pamoate Suspension | 10ml Bottle |
8.36 |
9.30 |
11.24 |
CP |
Each 5ml contains | with M. Cup |
|||||
Pyrantel Pamoate eq. to | ||||||
Pyrantel base-250mg |